Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Brentuximab vedotin (BV) demonstrated a pooled overall response rate (ORR) of 62.6% and complete response (CR) rate of 32.9% in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after four cycles. BV improved ORR by 22% compared to salvage chemotherapy in R/R cHL patients post-autologous stem cell transplantation (ASCT).
• For R/R cHL treated with BV, progression-free survival (PFS) rates were reported as 52.1% to 63.2% at 1 year, 45.2% to 56.2% at 2 years, and 31.9% to 33.0% at 5 years. Overall survival (OS) rates for BV were 68.2% to 82.7% at 1 year, 58.0% to 81.9% at 2 years, and 58.0% to 62.0% at 5 years. In post-ASCT cases, 5-year OS was 34%, and 5-year PFS was 31%.
• BV combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) showed significant benefits over CHOP in peripheral T-cell lymphoma (PTCL). Additionally, BV with doxorubicin, vinblastine, and dacarbazine (A+AVD) was more effective than ABVD (doxorubicin [Adriamycin(R)], bleomycin, vinblastine, and dacarbazine) in advanced-stage Hodgkin lymphoma (HL).
• Pembrolizumab and other PD-1 inhibitors provided higher quality of life (QoL) scores than BV in R/R cHL cases, indicating a favorable comparison in terms of patient-reported outcomes.
• Common adverse events (AEs) associated with BV included hematological toxicities, with neutropenia occurring in 13.3%-23% of patients, anemia in 8.8%-39.0%, thrombocytopenia in 4%-4.6%, and peripheral neuropathy in 3.3%-7.3% of patients. BV significantly increased the risk of both all-grade and high-grade AEs, particularly peripheral sensory neuropathy, pyrexia, nausea, vomiting, diarrhea, alopecia, and neutropenia.
• High-grade sensory neuropathy (relative risk [RR] 4.79) and high-grade neutropenia (RR 1.48) were reported to be significantly elevated in patients treated with BV.
• When compared to chemotherapy regimens such as ABVD and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), BV was generally tolerable, though it showed an increased risk of peripheral neuropathy and other adverse events (AEs). In older adults with classical Hodgkin lymphoma (cHL), pulmonary toxicity was more common with more than two cycles of bleomycin, while cumulative BV doses were associated with peripheral neuropathy.
• BV treatment in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) post-ASCT showed significant clinical response and survival benefits, with notable effectiveness in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) for peripheral T-cell lymphoma (PTCL). In older adults with cHL, BV was associated with increased toxicity, specifically pulmonary toxicity and peripheral neuropathy. Special dosing and timing considerations are advised for hemodialysis patients due to altered pharmacokinetics of BV. Pembrolizumab and similar inhibitors demonstrated superior QoL improvements in R/R cHL compared to BV.